Nutritional, Metabolic and Respiratory Status in Cystic Fibrosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

114 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-04-30

Study Completion Date

2020-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Diabetes is a important complication of cystic fibrosis (CF). The improved life expectancy of patients with cystic fibrosis, as a result of advances in medical therapy, has resulted in an increasing prevalence of cystic fibrosis-related diabetes (CFRD). CFRD is associated with accelerated pulmonary decline and increased mortality. Pulmonary effects are seen some years before the diagnosis of CFRD implying that impaired glucose tolerance may be very early detrimental. Insulin treatment is clearly indicated in patients with CFRD to control symptoms and reduce complications. However, at the state of impaired glucose tolerance or fasting hyperglycaemia, current screening methods are not suitable for the early management of hyperglycaemia.The recent introduction of the continuous glucose monitoring system (CGMS), which provides a continuous glucose profile, has revealed to be clinically relevant in the investigation of glucose excursions over a long period. This device, widely use in diabetic non cystic fibrosis patients, has been validated in non diabetic cystic fibrosis subjects. Previous studies of continuous glucose monitoring have been realized in CF patients with normal glucose tolerance and diabetes and compared with non CF controlThe aim of our study is to evaluate the glucose profile with continuous glucose monitoring the nutritional and respiratory status in cystic fibrosis subjects, according to their glucose tolerance.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Identification of Dysglycemia With Continuous Glucose Monitoring to Assess Clinical Evolution in Cystic Fibrosis

NCT05099939

Cystic Fibrosis

RECRUITING

Glucose Tolerance in Children With Cystic Fibrosis

NCT02569229

Glucose Intolerance Cystic Fibrosis

COMPLETED

Glycemic Monitoring in Cystic Fibrosis

NCT02211235

Cystic Fibrosis

COMPLETED

A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis

NCT06350149

Cystic Fibrosis

RECRUITING NA

Glucose Monitoring in Youth With Cystic Fibrosis During Pulmonary Exacerbations

NCT06546943

Cystic Fibrosis Pulmonary Exacerbation

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystic Fibrosis Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

abnormal glucose tolerance

Group Type OTHER

Urinary collect

Intervention Type PROCEDURE

Continuous Glucose Monitoring System (CGMS)

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Urinary collect

Intervention Type PROCEDURE

Continuous Glucose Monitoring System (CGMS)

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients 10 years and older with cystic fibrosis
* not known diabetics with fasting blood glucose \<1.26 g / l
* outside periods of exacerbation and / or glucocorticoid therapy
* affiliated to a social security scheme
* having received the results of the mandatory medical examination
* having signed an informed consent

Exclusion Criteria

* Patient transplanted lung and / or liver
* Subject during participation in an interventional clinical trial
* unable to give informed about the information
* patient under judicial protection
* patient under tutorship or curatorship
* pregnancy
* breastfeeding
* patient treated with the combination lumacaftor and ivacaftor

Minimum Eligible Age

10 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No